Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 7:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Kidney Carcinoma Clear all
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Renal Cancer, Von Hippel Lindau
Interventions
ZACTIMA (Vandetanib) (ZD6474)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced May 21, 2026, 7:23 PM EDT
Terminated Phase 1 Interventional Results available
View directory record Official record
Conditions
Advanced Solid Tumors, Metastatic Renal Cell Carcinoma
Interventions
Part 1: M8891
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
7
States / cities
New Haven, Connecticut • Indianapolis, Indiana • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced May 21, 2026, 7:23 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Kidney Cancer
Interventions
lenalidomide
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced May 21, 2026, 7:23 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions
gemcitabine hydrochloride, paclitaxel
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Up to 120 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
92
States / cities
Mobile, Alabama • Little Rock, Arkansas • Los Angeles, California + 59 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced May 21, 2026, 7:23 PM EDT
Active, not recruiting Phase 3 Interventional Results available
View directory record Official record
Conditions
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma
Interventions
Pembrolizumab, Nivolumab, Atezolizumab, Durvalumab, Avelumab
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
377
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 260 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced May 21, 2026, 7:23 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Clear Cell Carcinoma, Phase 1, Growth Factor
Interventions
Lymphodepleting chemotherapy, Dexamethasone, Fludarabine, Cyclophosphamate, TGFBR-2 KO CD70 CAR NK
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced May 21, 2026, 7:23 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Neutropenia, Sarcoma
Interventions
voriconazole
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 11 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
7
States / cities
Orange, California • San Diego, California • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced May 21, 2026, 7:23 PM EDT
Active, not recruiting Not applicable Interventional
View directory record Official record
Conditions
Brain Metastases
Interventions
Whole brain radiation, Stereotactic radiation (SRS)
Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced May 21, 2026, 7:23 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Metastatic Cancer, Metastatic Renal Cancer, Metastatic Melanoma
Interventions
PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes, Aldesleukin, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced May 21, 2026, 7:23 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Renal Cancer, Melanoma
Interventions
Aldesleukin, Sorafenib
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 19, 2017 · Synced May 21, 2026, 7:23 PM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Interventions
bempegaldesleukin, sunitinib, nivolumab, cabozantinib
Biological · Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
20
States / cities
Anchorage, Alaska • Goodyear, Arizona • Little Rock, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced May 21, 2026, 7:23 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced or Metastatic Solid Tumors, Prostate Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Intrahepatic Cholangiocarcinoma, Squamous Cell Anal Cancer, Squamous Cell Penile Carcinoma, Squamous Cell Vulvar Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma
Interventions
XmAb®22841, Pembrolizumab (Keytruda®)
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
28
States / cities
Encinitas, California • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced May 21, 2026, 7:23 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma, Metastatic Melanoma, High-dose Interleukin-2
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
16 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced May 21, 2026, 7:23 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Kidney Cancer
Interventions
Perifosine
Drug
Lead sponsor
AEterna Zentaris
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
3
States / cities
Louisville, Kentucky • Morristown, New Jersey • Armonk, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2018 · Synced May 21, 2026, 7:23 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Ewing Sarcoma, Wilms Tumor, Desmoplastic Small Round Cell Tumor
Interventions
Enoblituzumab
Drug
Lead sponsor
MacroGenics
Industry
Eligibility
1 Year to 35 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Palo Alto, California • Bethesda, Maryland • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced May 21, 2026, 7:23 PM EDT
Withdrawn Not applicable Interventional
View directory record Official record
Conditions
Breast Carcinoma, Colon Carcinoma, Kidney Carcinoma, Lymphoma, Non-Small Cell Lung Carcinoma, Prostate Carcinoma
Interventions
Internet-Based Intervention, Survey Administration
Other
Lead sponsor
University of Southern California
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced May 21, 2026, 7:23 PM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Human Papillomavirus Infection, Human Papillomavirus-Related Carcinoma
Interventions
Biospecimen Collection, HPV Self-Collection, Questionnaire Administration, Recombinant Human Papillomavirus Nonavalent Vaccine
Procedure · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 49 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced May 21, 2026, 7:23 PM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer, Head and Neck Cancer, Lung Cancer, Renal Cell Carcinoma (RCC), Bladder Cancer, UC (Urothelial Cancer), Mesothelioma
Interventions
INCB001158, Pembrolizumab
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
13
States / cities
Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced May 21, 2026, 7:23 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Kidney Cancer
Interventions
everolimus, placebo
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
1,545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
1002
States / cities
Birmingham, Alabama • Mobile, Alabama • Fairbanks, Alaska + 609 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced May 21, 2026, 7:23 PM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
AGS-003
Drug
Lead sponsor
Argos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced May 21, 2026, 7:23 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
High Dose IL-2, SBRT
Biological · Radiation
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced May 21, 2026, 7:23 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Carcinoma of Urinary Tract, Urethral Carcinoma, Carcinoma of Ureter, Carcinoma of Renal Pelvis
Interventions
Docetaxel, Ramucirumab DP, Icrucumab
Drug · Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
26
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2019 · Synced May 21, 2026, 7:23 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Renal Cell Carcinoma, Kidney Cancer
Interventions
Durvalumab, Tremelimumab
Drug
Lead sponsor
Moshe Ornstein
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Minneapolis, Minnesota • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced May 21, 2026, 7:23 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Hereditary Leiomyomatosis and Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma, Sporadic Papillary Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Atezolizumab, Bevacizumab, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Computed Tomography with Contrast, Erlotinib, Magnetic Resonance Imaging, Positron Emission Tomography, Sodium Fluoride F-18
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
13
States / cities
La Jolla, California • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced May 21, 2026, 7:23 PM EDT